GT BioPharma’s Next Generation Camelid TriKE® Nanobody Platform Highlighted at ESMO Congress 2021

BEVERLY HILLS, Calif.: BEVERLY HILLS, Calif., Sept. 20, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced Dr. Jeffrey Miller's mini-oral presentation at the European...

Click to view original post